Portal de investigação
Author's Reply: ``Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?''
Autores da FMUP
Participantes de fora da FMUP
- Sousa, Paula
Unidades de investigação
Abstract
[No abstract available]
Dados da publicação
- ISSN/ISSNe:
- 1590-8658, 1878-3562
- Tipo:
- Editorial Material
- Páginas:
- 532-533
- Link para outro recurso:
- www.scopus.com
Digestive and Liver Disease Elsevier
Documentos
- Não há documentos
Filiações
Keywords
- BIOLOGIC-NAIVE PATIENTS; CROHNS-DISEASE; ADALIMUMAB
Proyectos asociados
Gut microbiome and IBD therapy: an interplay?
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (GutIBD) . 2021
Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (IronIBD) . 2021
Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (4WARD) . 2021
Isolated Ulceration of Crohn’s Anastomosis
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2022
Burden of Inflammatory Bowel Disease in Portugal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico (Inflammatory Bowel) . 2023
Therapeutic Drug Monitoring: An Emergent Approach in Inflammatory Bowel Disease
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2019
Citar a publicação
Sousa P,Magro F. Author's Reply: ``Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?''. Dig. Liver Dis. 2024. 56(3):p. 532-533. IF:4,500. (2).
